Company news
Allergy Therapeutics Plc (LSE:AGY) news
Allergy Therapeutics Plc news releases on 6ix. Latest, Jan 13, 2023: NOTICE OF 2022 ANNUAL GENERAL MEETING
Press releases — page 3
NOTICE OF 2022 ANNUAL GENERAL MEETING
January 13, 2023
Second Price Monitoring Extn
December 29, 2022
Price Monitoring Extension
December 29, 2022
Key updates on Grass MATA MPL and VLP Peanut
December 8, 2022
Appointment of Non-Executive Directors
December 6, 2022
Appointment of Interim CFO
November 21, 2022
Allergy to resume UK manufacturing production
October 28, 2022
Allergy Therapeutics - Result of GM
October 17, 2022
UK manufacturing update
October 4, 2022
Allergy Therapeutics at Investor Meet Company
September 29, 2022
Unaudited Preliminary Results 2022
September 29, 2022
Subscription and Debt Financing
September 29, 2022
Allergy Therapeutics at H.C. Wainwright Conference
September 5, 2022
Trading Update and Notice of Results
July 15, 2022
Allergy Therapeutics at EAACI Congress 2022
July 1, 2022
Nick Wykeman to step down as CFO
May 26, 2022
Allergy Therapeutics shares data at WAO-BSACI
April 25, 2022
Allergy Therapeutics at Cowen Health Conference
March 8, 2022
Allergy Therapeutics plc - Interim Results
March 3, 2022
Allergy Therapeutics shares positive new data
March 1, 2022
Secures new revolving credit facility
February 2, 2022
FDA clearance of IND application for VLP Peanut
January 26, 2022
Half Year Trading Update & Notice of Results
January 13, 2022
Allergy Therapeutics: Granting of Awards
November 25, 2021
Director Dealings
November 11, 2021
Cheryl MacDiarmid appointed to Board of Directors
October 27, 2021
Allergy announces positive G309 results
October 25, 2021
Annual Report and AGM Notification
October 7, 2021
Preliminary Results for Year ended 30 June 2021
September 23, 2021
ImmunoBON voted Most Innovative Product of 2021
September 16, 2021
Secondary endpoints from VLP Peanut 001
September 13, 2021
Allergy to Present at H.C. Wainwright Conference
September 9, 2021
Allergy to host KOL webinar on VLP Peanut
September 7, 2021
Successful primary outcome of VLP Peanut 001
August 3, 2021
Trading update for the year ended 30 June 2021
July 14, 2021
AGY to present key scientific findings at EAACI
July 8, 2021
Trading Update
June 24, 2021
Completion of treatment phase in G309 study
May 6, 2021
Allergy Therapeutics : Appointment of new Group auditors
April 19, 2021
Appointment of new Group auditors
April 16, 2021
Vesting of Awards under Long Term Incentive Plan
March 31, 2021
Pledge of Shares
March 26, 2021
AGY to Present at H.C. Wainwright Conference
March 8, 2021
Interim Results for six months ended 31 Dec 2020
March 3, 2021
Block Listing Return and Total Voting Rights
January 15, 2021
Half Year Trading Update 2021 & Notice of Results
January 13, 2021
Initiation of peanut allergy biomarker study
January 5, 2021
Grant of Awards under Long Term Incentive Plan
November 20, 2020
Annual Report & Accounts and AGM Notification
November 10, 2020
Initiation of Grass MATA MPL exploratory study
October 26, 2020